Responsable: Inmaculada Robina Ramírez
Tipo de Proyecto/Ayuda: 6º Programa Marco de la U.E.
Referencia: LSHB-CT-2003-503480
Web: http://cordis.europa.eu/projects/rcn/78709_en.html
Fecha de Inicio: 01-01-2004
Fecha de Finalización: 30-06-2007

Empresa/Organismo financiador/es:

• Commission of the European Communities

Socios:

• Katholieke Universiteit Leuven (Myriam Witvrouw)
• Fundació IrsiCaixa (José A. Esté)
• Institut National de la Santé et de la Recherché Médicale (Jean-Luc Darlix)
• Universidad de Barcelona (Jaume Vilarrasa)
• University of Messina (Alba Chimirri)
• Georg-Speyer-Haus (Ursula Dietrich)
• Centre National de la Recherche Scientifique (Gilles Divita)
• Johann Wolfgang Goethe Universitat Frankfurt (Joachim W. Engels)
• Moscow State University (Marina Gottikh)
• Heriot-Watt University (Nicola Howarth)
• Utrecht University (Robert Kaptein)
• University of Heidelberg (Oliver Keppler)
• University of Szeged (Lajos Kovacs)
• Consiglio Nazionale delle Ricerche (Giovanni Maga)
• University of Siena (Silvio Massa)
• University Louis Pasteur (Yves Mely)
• Ecole Normale Supérieure de Cachan (Jean-François Mouscadet)
• Universitaet Luebeck (Tobias Restle)
• Institute of Nuclear Sciences VINCA (Veljko Veljkovic)
• Universidad Miguel Hernández (José Villalaín-Boullón)
• Ecole Polytechnique Fédérale de Lausanne (Pierre Vogel)
• Medivir AB (Lotta Vrang)
• Hybrigenics SA (Gerlinde Lenzen)

Equipo:

• Investigadores:
  • Francisca Cabrera Escribano
  • Ana Teresa Carmona Asenjo
  • José Luis Espartero Sánchez
  • Antonio José Moreno Vargas
  • Yolanda Vera Ayoso

Becarios:

• Nombramiento de Becario:
  • Mario Bautista Trigueros
  • Alessandro Ferrali
  • Cristina González Romero
  • Jorge Illanes Núñez
  • Lidia Molina Sanz
  • Agnieszka Anna Szczepanska

Resumen del proyecto:

Anti-HIV drugs, used at present in the clinic, target the viral reverse transcriptase (RT) or protease (PR). Combination therapies are the current standard of care. However, as a result of insufficient drug plasma levels or of insufficient inhibitory power of the chosen drug combination, drug resistant strains emerge, resulting in therapeutic failure. Consequently, there is a continuing need for new anti-HIV drugs to be used in combination with the current drugs, which should represent novel chemical entities targeting known targets (viral entry,reverse transcription), or should act on new viral targets of the HIV replication cycle (e.g. nucleocapsid, integrase) or interfere with cellular co-factors required for HIV replication.

The general objective of TRIoH is to integrate the different research efforts from different European partners on novel anti-HIV molecules targeting viral replication and integration. Our central scientific paradigm is the molecular continuum between the different HIV early replication steps starting with viral entry and leading to integration. We will use multidisciplinary proteomics approaches to study the basic science of HIV replication andintegration. There is special focus on the identification of new, cellular host factors. Our research will foster a technological platform of academic and industrial partners and result in more efficient development of new drugs and therapies by providing new assays and new targets. Basic science, biotechnology and provocative chemistry will guide the development of new HIV therapeutics. Identified lead compounds of participating partners will be developed preclinically, ready for Phase 1 clinical trials. Different Biotech SMEs are actively involved in the development and valorisation program. Our project will include all aspects of present day drug development starting with chemical synthesis up to preclinical evaluation in animal models.